U.S. Healthtech Stock News

In early December 2025, General Dynamics promoted long-time executive Danny Deep to president, announced a planned controller transition, and declared a regular US$1.50 quarterly dividend, while also facing potential cancellation of the U.K.’s £6.30 billion Ajax armored vehicle program after safety concerns halted use of the fleet. This combination of leadership changes, capital return continuity, and heightened contract risk spotlights how General Dynamics balances governance stability with...

Recently, KeyBanc upgraded Carpenter Technology to an Overweight rating and the company completed a US$700 million 5.625% senior notes offering due 2034 to refinance earlier, higher‑coupon debt and strengthen its balance sheet. The upgrade highlights how resurgent aerospace demand, higher pricing and improved cost discipline could enhance Carpenter Technology’s earnings power as Boeing 737/MAX production resumes. Next, we’ll explore how this refinancing-driven balance sheet improvement could...

Solid Power (SLDP) is back in focus after director Erik Anderson sold 30,000 shares and the company adjusted its Executive Change in Control and Severance Plan, raising fresh questions about leadership incentives and governance. See our latest analysis for Solid Power. Those governance tweaks are landing after a sharp run, with the share price at 5.12 and a year to date share price return of 147.34 percent. However, the recent 30 day share price return of negative 27.89 percent suggests...

Credicorp (NYSE:BAP) has quietly delivered a strong run, with shares up roughly 7% over the past month and about 50% this year, far outpacing many regional financial peers. See our latest analysis for Credicorp. That climb has not come out of nowhere. The stock’s roughly 50 percent year to date share price return and triple digit multi year total shareholder returns suggest investors are steadily reassessing its growth profile and risk backdrop. If Credicorp’s momentum has caught your eye, it...

Rezolute recently scheduled a special call to discuss results from its Phase 3 sunRIZE study in congenital hyperinsulinism, a rare pediatric disorder with significant unmet medical need. The combination of pivotal trial readout and a broad shelf registration filing highlights how Rezolute may be preparing for potential commercialization and future financing flexibility. With Phase 3 sunRIZE data in focus, we’ll now examine how this potential inflection point could reshape Rezolute’s overall...

If you are wondering whether Cardinal Health is still a smart buy after its massive run, or if you are arriving late to the party, this breakdown will help you think through whether the current price makes long term sense. The stock has cooled slightly in the short term, slipping around 0.8% over the last week and 3.5% over the last month, but it is still up roughly 67.9% year to date and about 71.2% over the last year, capping a 315.0% gain over five years. Recent headlines have focused on...

Wondering if H&R Block is quietly becoming a bargain, or if the market is signaling deeper issues with the business? This breakdown will help you decide whether HRB deserves a spot on your watchlist. The stock has slipped recently, down 2.4% over the last week, 12.5% over the past month, and 21.4% year to date. However, longer term holders are still sitting on gains of 9.2% over 3 years and 209.2% over 5 years. Some of this pullback reflects shifting sentiment around consumer services and...

If you have been wondering whether CME Group is still worth buying after this long run up, you are not alone. This article is going to unpack what the current price really implies. Even after a recent pullback of around 2.9% over the last week and 3.9% over the last month, the stock is still up 14.4% year to date and about 18.2% over the past year, building on a powerful 74.0% three year and 78.8% five year climb. Those moves have come as CME continues to sit at the center of global...

If you are wondering whether Cohen & Steers is a value trap or a quiet opportunity hiding in plain sight, this breakdown can help you assess whether the current share price really lines up with the underlying business. The stock has drifted lower recently, with shares down 0.9% over the last week, 7.6% over the past month, and 32.3% year to date. This naturally raises questions about whether sentiment has moved beyond what the fundamentals justify. Much of the move is tied to shifting...

If you have ever wondered whether Autodesk is actually worth its current price tag, you are not alone. This article is designed to unpack what the market might be missing. The stock has been choppy lately, slipping around 2.3% over the last week and only 0.5% over the past month, but it is still up about 2.3% year to date and 50.0% over three years. This hints at a longer term growth story despite a slightly negative 1 year return of 2.4%. Recent attention on Autodesk has centered on its...

C3.ai (AI) just landed a meaningful endorsement from the U.S. Army’s Rapid Capabilities and Critical Technologies Office, which is adopting its AI platform to manage contested logistics and keep front line units supplied. See our latest analysis for C3.ai. Even with marquee wins like the Army and a new HHS data platform deal, C3.ai’s share price return has slid sharply this year, with the latest close at $15.82. Its three year total shareholder return is still positive, suggesting long term...

If you are wondering whether Redwire at around $7.50 is a bargain or a value trap, you are not alone. That is exactly what we are going to unpack. The stock has jumped 34.3% over the last week and 21.2% over the past month, but it is still down 56.1% year to date and 35.9% over the last year, even after a 3 year gain of 281.6%. Those swings have come as investors digest a steady drumbeat of contract wins and broader enthusiasm for space infrastructure and defense related spending, which have...

Insider selling after a 300% rally at Seagate Technology Holdings (STX) has grabbed attention, but the bigger story is that institutional buyers are still stepping in as analysts stay broadly constructive. See our latest analysis for Seagate Technology Holdings. That backdrop helps explain why the stock’s latest move, with a 1 day share price return of 5.68 percent and a 7 day share price return of 15.56 percent, comes on top of a powerful year to date share price return of 246.01 percent and...

In the past week, Floor & Decor Holdings reported a mixed quarter with revenue rising 5.5% while comparable sales slipped 1.2%, as management cut store buildout costs, managed a CEO transition, and reaffirmed plans to open about 20 stores annually despite housing market pressures. At the same time, the company is leaning into digital innovation, expanded kitchen and outdoor offerings, and supply chain improvements to capture market share even as weak same-store sales and an 8.8% return on...

Wondering if Lyft at around $20 a share is still a comeback story in the making, or if the easy money has already been made? You are not alone, and that is exactly what we are going to unpack here. Despite a sharp pullback over the last week and month, with the stock down 9.8% over 7 days and 16.0% over 30 days, Lyft is still up 48.9% year to date and 36.8% over the past year. This highlights how quickly sentiment around the name can swing. Recent headlines have focused on Lyft sharpening...

American Assets Trust (AAT) just attracted a fresh $4.4 million stake from Argosy-Lionbridge Management, right after the REIT nudged its full year FFO guidance higher, a combination that naturally draws value focused investors. See our latest analysis for American Assets Trust. The new Argosy-Lionbridge stake and slightly higher FFO guidance land against a weaker backdrop, with a year to date share price return of negative 26.9 percent and a one year total shareholder return of negative 26.55...

Primo Brands (PRMB) has quietly slid almost 50% over the past year, even as its annual revenue still edges higher and earnings swing sharply. That disconnect is exactly what has value focused investors paying closer attention. See our latest analysis for Primo Brands. Over the past year, Primo Brands’ 1 year total shareholder return of around negative 50 percent, alongside a roughly negative 35 percent 3 month share price return from about 15 dollars, suggests sentiment has been fading even...

Wondering if Marsh & McLennan Companies is still worth buying after a long run up, or if the market has finally pushed this blue chip too far? This article will walk through what the current share price really implies about future returns. The stock has drifted lower recently, with shares down 1.2% over the last week, 0.5% over the last month, and about 14.9% over the past year, even though the 3 year and 5 year returns of 12.5% and 64.1% still show a solid long term compounding story. That...

Earlier this month, Lineage outlined its operational excellence and digital strategy, emphasizing the rollout of its proprietary LinOS warehouse execution system to more than 250 locations by 2029 and projecting about US$110 million in incremental annual EBITDA over the next three to five years. The company has already invested US$250 million in LinOS, committed a further US$200 million through 2030, and is targeting a forecasted return on invested capital of 24%, while also linking recent...

Earlier this month, Hyatt Hotels Corporation expanded its luxury offerings by enabling World of Hyatt members to book 15 Asilia Africa safari camps across Kenya, Tanzania, and Uganda via Hyatt’s channels, while also appointing Puneet Baijal as General Manager of Hyatt Regency Mumbai. This move extends Hyatt’s loyalty ecosystem into high-end experiential travel and aligns the brand with community-led conservation, which may appeal to environmentally conscious premium guests. Next, we’ll...

United Therapeutics (UTHR) is back in focus after several senior executives disclosed sizable stock sales, including Chairperson and CEO Martine Rothblatt, prompting investors to reassess what this insider activity might signal for the shares. See our latest analysis for United Therapeutics. The insider moves are landing against a backdrop of strong momentum, with a roughly 19.7 percent 3 month share price return and about 226.6 percent 5 year total shareholder return, suggesting investors...

Earlier this quarter, New York-based D1 Capital Partners lifted its stake in Flowserve by nearly 5.8 million shares to about 7.5 million, a position valued at roughly US$397.5 million at quarter-end. This move came alongside Flowserve reporting consistent operations, expanding margins, stronger cash generation, and a higher mix of aftermarket revenue, underscoring rising confidence in its business quality. We’ll now examine how D1’s larger ownership position and Flowserve’s margin and cash...

Hess Midstream LP recently outlined its 2026 outlook, guiding to net income of US$650 million–US$700 million with largely steady oil and gas throughput, while also significantly trimming capital spending and signaling continued distribution growth backed by free cash flow. At the same time, the company reshaped its board by naming existing director Kristi McCarthy as chair and adding Chevron executive Barbara Harrison, moves that tighten its alignment with Chevron’s long-term plans for...

Rapport Therapeutics recently reported additional Phase 2a data for its epilepsy candidate RAP-219, showing statistically significant improvements in seizure severity and patient-reported functioning in adults with drug-resistant focal onset seizures, and outlined plans to start two pivotal Phase 3 trials in 2026 following an upcoming end-of-Phase 2 meeting with the FDA. An interesting element for investors is the PET receptor occupancy data, which links RAP-219’s brain target engagement to...